Download our whitepaper,
"Melanoma Clinical Trials: Navigating Diagnosis, Endpoints, and Challenges"
What's Inside:
- Key FDA-Approved Pivotal Endpoints for Melanoma Clinical Trials.
- Optimizing Recruitment with Adaptive Trial Designs for Melanoma.
- Comprehensive Analysis of FDA-Approved Melanoma Drugs.
- How Diagnostic Criteria for Melanoma Have Evolved and Impact Research.
- Overcoming Common Pitfalls in Melanoma Clinical Trials.
- And additional insights to drive your trial's success.
Access your complimentary whitepaper today:
Melanoma
Melanoma is a form of skin cancer that primarily develops from melanocytes, the cells responsible for producing pigment in the skin.
It often begins as a change in an existing mole or the appearance of a new, unusual growth on the skin.
This advanced understanding has led to the creation of therapies that not only target the visible symptoms but also address the underlying biological mechanisms of the disease.
iNGENū's team of experienced researchers and clinicians is dedicated to advancing melanoma research. Through innovative trial designs and patient-focused strategies, we are committed to accelerating the development of new treatments that can improve the lives of those affected by melanoma.
65%
of Melanomas develop on parts of the body that receive little sun exposure
Melanoma diagnoses grew
3x
in the last 40 years in the USA
75%
of skin cancer deaths are caused by Melanoma
Our clinical team has over
120
years of combined clinical trial experience